This study aims to test a new way of giving a medicine called ocrelizumab to people with Multiple Sclerosis (MS). MS is a disease where the immune system attacks the nerves. The study is for people who have been using certain MS medicines but want to switch. Ocrelizumab will be given under the skin (subcutaneously) with another helper medicine called rHuPH20. Participants need to have been diagnosed with Relapsing MS (RMS) or Primary Progressive MS (PPMS). They should not have responded poorly to previous treatments or have serious infections.
- Study involves switching from previous MS treatments to ocrelizumab.
- Participation requires specific health conditions and previous treatment history.
- Some people with certain infections or allergies cannot join.
Join if you have RMS or PPMS and are switching from another MS medicine like ofatumumab, ublituximab-xiiy, or ocrelizumab given through an IV. You should not have certain severe reactions or infections to be eligible. This could be a chance to try a new way of taking ocrelizumab with help from rHuPH20.